Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rheumatology/keaa632 | DOI Listing |
J Acoust Soc Am
January 2025
Department of Biology, University of Aarhus, Aarhus, 8000, Denmark.
Gransier and Kastelein [J. Acoust. Soc.
View Article and Find Full Text PDFAm J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
View Article and Find Full Text PDFJ Clin Med
January 2025
Otorhinolaryngology and Head and Neck Surgery Department, University Medical Centre Utrecht, PB 85500, 3508 GA Utrecht, The Netherlands.
Dear Editor, [...
View Article and Find Full Text PDFDiagnostics (Basel)
January 2025
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2000, Australia.
We appreciate the interest of Troisi and his colleagues [...
View Article and Find Full Text PDFDiagnostics (Basel)
January 2025
Ophthalmologic Unit, Salerno Hospital University, 84100 Salerno, Italy.
We read with great interest the recent article by Cabrera-Aguas M [...
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!